| - |
Safinamide methansulfonate |
Xadago® |
For the treatment of adult patients with idiopathic Parkinson’s disease. |
Rapid Review Complete |
6th July 2016 |
 |
| - |
Sapropterin |
Kuvan® |
For the treatment of phenylketonuria (PKU). |
Full HTA Assessment |
15th September 2017 |
|
| - |
Sarilumab |
Kevzara® |
In combination with methotrexate (MTX) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARD). Sarilumab can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate. |
Rapid Review Complete |
4th October 2017 |
|
| - |
Sebelipase alfa |
Kanuma® |
Is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency. |
Assessment Process Complete |
8th June 2018 |
|
| - |
Secukinumab |
Cosentyx® |
For the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy |
Rapid Review Complete |
16th December 2015 |
|
| - |
Secukinumab |
Cosentyx® |
For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
Assessment Process Complete |
16th September 2015 |
|
| - |
Secukinumab |
Cosentyx® |
Alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. |
Rapid Review Complete |
16th December 2015 |
|
| - |
Selexipag |
Uptravi® |
For the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies. |
Assessment Process Complete |
21st May 2018 |
|
| 21020b |
Selpercatinib |
Retsevmo® |
For the treatment of adult patients with advanced RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with lenvatinib and/or sorafenib. |
Awaiting HTA submission from Applicant |
7th July 2021 |
|
| 21020a |
Selpercatinib |
Retsevmo® |
Is indicated for adult and adolescent patients, 12 years and older, with advanced RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and/or vandetanib. |
Awaiting HTA submission from Applicant |
7th July 2021 |
|
| 21021 |
Selparcatinib |
Retsevmo® |
For the treatment of adults with advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. |
Awaiting HTA submission from Applicant |
29th June 2021 |
|
| 22032 |
Selumetinib |
Koselugo® |
For the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above. |
Full HTA resubmission received 29/01/2024* |
29th January 2024 |
|
| - |
Semaglutide |
Ozempic® |
For the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise/as monotherapy when metformin is considered inappropriate due to intolerance or contraindications/in addition to other medicinal products for the treatment of diabetes |
Rapid Review Complete |
10th April 2018 |
|
| 20011 |
Semaglutide |
Rybelsus® |
For the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise: (a) as monotherapy when metformin is considered inappropriate due to intolerance or contraindications. (b) in combination with other medicinal products for the treatment of diabetes. |
Assessment Process Complete |
17th February 2021 |
|
| 22029 |
Semaglutide |
Wegovy® |
Is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity), or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. |
Rapid Review Complete |
9th June 2022 |
|
| - |
Sildenafil |
Revatio® |
(a) For the treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity. (b) For the treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. |
Rapid Review Complete |
23rd May 2014 |
|
| - |
Simeprevir |
Olysio® |
In combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients as part of a triple therapy regimen (co-administered with PegInterferon + Ribavirin) to treat hepatitis C virus (HCV) Genotypes 1 and 4 who are treatment naïve or have previously been treated. |
Rapid Review Complete |
11th July 2014 |
|
| - |
Simeprevir |
Olysio® |
In combination with Sofosbuvir for the treatment of chronic hepatitis C (CHC) in adult patients who are intolerant to or ineligible for interferon therapy, and are in urgent need of treatment. |
Assessment Process Complete |
13th March 2015 |
|
| 19053 |
Siponimod |
Mayzent® |
For the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. |
Assessment Process Complete |
26th February 2021 |
|
| - |
Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml |
Hyaneb® |
Is particularly indicated in patients with cystic fibrosis and in patients with bronchiectasis. Hyaneb® is classified as a medical device and carries a CE mark. |
Rapid review complete |
25th March 2014 |
|
| - |
Sodium Hyaluronate |
Hyloforte® 0.2% |
For the treatment of mild to moderate form of dry eye. |
Rapid review complete |
31st January 2014 |
|
| - |
Sodium Hyaluronate |
Hylotear® 0.1% |
For the treatment of mild to moderate form of dry eye. |
Rapid review complete |
31st January 2014 |
|
| 20043 |
Sodium hydrogen carbonate |
Thamicarb® |
For metabolic acidosis in chronic kidney disease. |
Rapid review complete |
23rd November 2020 |
|
| - |
Sodium phenylbutyrate |
Pheburane® |
As adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase. |
Rapid review complete |
7th August 2013 |
|
| - |
Sofosbuvir |
Solvaldi® |
In combination with other medicinal products for the treatment of Chronic Hepatitis C in adults. |
Assessment process complete |
13th November 2014 |
|
| - |
Sofosbuvir/Velpatasvir |
Epclusa® |
For the treatment of chronic hepatitis C virus (HCV) infection in adults |
Rapid review complete |
23rd August 2016 |
|
| - |
Sofosbuvir/velpatasvir |
Epclusa® |
For the treatment of chronic hepatitis C virus (HCV) infection in adults. This indication covers all genotypes (GT1, 2, 3, 4, 5 and 6) i.e. pangenotypic. |
Rapid review complete |
19th October 2017 |
|
| - |
Sofosbuvir/Velpatasvir/Voxilaprevir |
Vosevi® |
For the treatment of chronic hepatitis C virus (HCV) infection in adults – pangenotypic i.e. all genotypes (GT1, 2, 3, 4, 5 and 6). |
Rapid review complete |
15th November 2017 |
|
| 22017 |
Solriamfetol |
Sunosi® |
To improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy). |
Rapid review complete |
11th April 2022 |
|
| 23060 |
Somapacitan |
Sogroya® |
Somapacitan (Sogroya®) is indicated for the replacement of endogenous growth hormone in children aged three years and above and adolescents with growth failure due to growth hormone deficiency (GHD), and in adults with GHD. |
Rapid Review Complete |
27th November 2023 |
|
| 22010 |
Somatrogon |
Ngenla® |
For the treatment of children and adolescents from three years of age with growth disturbance due to insufficient secretion of growth hormone |
Rapid review complete |
25th March 2022 |
|
| 21070 |
Sotorasib |
Lumykras® |
As monotherapy for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy. |
Rapid review complete |
25th January 2022 |
|
| - |
St Johns Wort |
Pacifa® |
For the short term treatment of mild depressive symptoms. |
Rapid review complete |
29th May 2015 |
|
| - |
Stiripentol |
Diacomit® |
In conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet’s syndrome) whose seizures are not adequately controlled with clobazam and valproate |
Assessment process complete |
3rd May 2019 |
|
| - |
Sublingual Immunotherapy |
Grazax® |
For the Prevention of Seasonal Grass Pollen-Induced Rhinoconjunctivitis. |
Rapid review complete |
4th September 2007 |
|
| - |
Sufentanil |
Zalviso® |
For the management of acute moderate to severe post-operative pain in adult patients. |
Assessment process complete |
22nd March 2016 |
|
| __ |
Sufentanil Citrate |
Dzuveo® |
For the management of acute moderate to severe pain in adult patients |
Rapid Review Complete |
22nd December 2023 |
|
| - |
Sunitinib |
Sutent® |
As second-line treatment of patients with gastro-intestinal stromal tumours (GIST); As second line treatment for patients with metastatic renal cell carcinoma (mRCC) |
Assessment process complete |
9th November 2006 |
|
| - |
Tadalafil |
Adcirca® |
In adults for the treatment of pulmonary arterial hypertension (PAH) classified as World Health Organisation (WHO) Functional Class (FC) II and III, to improve exercise capacity. |
Rapid Review Complete |
27th May 2014 |
|
| 20017 |
Tafamidis |
Vyndaqel® |
For the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy. |
Assessment process complete |
25th September 2020 |
|
| - |
Tafamidis meglumine |
Vyndaqel® |
For the treatment of transthyretin amyloidosis in adult patients with stage I symptomatic polyneuropathy to delay peripheral neurologic impairment. |
Rapid Review Complete |
10th May 2018 |
|
| 22008 |
Tafasitamab |
Minjuvi® |
In combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem-cell transplant (ASCT). |
Rapid Review Complete |
15th February 2022 |
|
| - |
Tafluprost |
Saflutan® |
For the reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension. |
Rapid Review Complete |
9th April 2011 |
|
| 19032 |
Talazoparib |
Talzenna® |
As monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. |
Assessment process complete |
18th September 2020 |
|
| 23074 |
Talazoparib |
Talzenna® |
Talazoparib (Talzenna®) in combination with enzalutamide is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. |
Rapid Review Complete |
21st December 2023 |
|
| - |
Talimogene laherparepvec |
Imlygic® |
For the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease. |
Rapid Review Complete |
15th March 2016 |
|
| 23057 |
Talquetamab |
Talvey® |
Talquetamab is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. |
Awaiting full HTA submission from Applicant |
23rd January 2024 |
|
| - |
Tapentadol |
Palexia® |
For the management of adult patients with severe chronic/acute pain. |
Assessment process complete |
13th April 2011 |
|
| 23064 |
Tebentafusp |
Kimmtrak® |
Tebentafusp is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. |
Rapid Review Complete |
13th November 2023 |
|
| 22064 |
Teclistamab |
Tecvayli® |
As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. |
Awaiting response from Applicant |
7th March 2024 |
|
